Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review

被引:56
|
作者
Dimitrakopoulou-Strauss, Antonia [1 ]
Ronellenfitsch, Ulrich [2 ]
Cheng, Caixia [1 ]
Pan, Leyun [1 ]
Sachpekidis, Christos [1 ]
Hohenberger, Peter [2 ]
Henzler, Thomas [3 ]
机构
[1] German Canc Res Ctr, Clin Cooperat Unit Nucl Med, Neuenheimer Feld 280, D-69120 Heidelberg, Germany
[2] Heidelberg Univ, Med Fac Mannheim, Univ Med Ctr Mannheim, Div Surg Oncol & Thorac Surg,Dept Surg, Mannheim, Germany
[3] Heidelberg Univ, Med Fac Mannheim, Univ Med Ctr Mannheim, Inst Clin Radiol & Nucl Med, Mannheim, Germany
关键词
Molecular imaging; PET; GIST; Oncology; Therapy monitoring; Personalized medicine; POSITRON-EMISSION-TOMOGRAPHY; DUAL-ENERGY CT; IMATINIB MESYLATE TREATMENT; SOFT-TISSUE SARCOMA; COMPUTED-TOMOGRAPHY; EARLY PREDICTION; PHASE-II; EVALUATION CRITERIA; CHOI CRITERIA; FOLLOW-UP;
D O I
10.1007/s40336-017-0229-8
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Improvement of the therapeutic approaches in gastrointestinal stromal tumors (GIST) by the introduction of targeted therapies requires appropriate diagnostic tools, which allow sufficient assessment of therapeutic response, including differentiation of true progression from pseudoprogression due to myxoid degeneration or intratumoral hemorrhage. In this literature review the impact and limitations of different imaging modalities used in GIST therapy monitoring are discussed. Methods PubMed and Cochrane library search were performed using appropriate keywords. Overall, 39 original papers fulfilled the defined criteria and were included in this systematic review. Results Morphological imaging modalities like computed tomography (CT) are primarily used for both diagnosis and therapy monitoring. However, therapy with tyrosine kinase inhibitors and other targeted therapies in GIST may lead only to a minor tumor volume reduction even in cases of response. Therefore, the use of Response Evaluation Criteria in Solid Tumors (RECIST) has limitations. To overcome those limitations, modified response criteria have been introduced for the CT-based therapy assessment, like the Choi criteria as well as criteria based on dual energy CT studies. Functional imaging techniques, mostly based on FDG PET-CT are in use, in particular for the assessment of early treatment response. Conclusions The impact and the limitations of PET-based therapy monitoring, as well as its comparison with CT, MRI and survival data are discussed in this review. CT is still the standard method for the evaluation of therapy response despite its several limitations. FDG PET-CT is helpful for the assessment of early therapy response; however, more prospective data are needed to define its role as well as the appropriate time intervals for therapy monitoring. A multiparametric evaluation based on changes in both morphological and functional data has to be assessed in further prospective studies.
引用
收藏
页码:183 / 197
页数:15
相关论文
共 50 条
  • [21] Molecular targets in Gastrointestinal Stromal Tumors (GIST) therapy
    Braconi, C.
    Bracci, R.
    Cellerino, R.
    CURRENT CANCER DRUG TARGETS, 2008, 8 (05) : 359 - 366
  • [22] Surgical Therapy for Gastrointestinal Stromal Tumors (GIST) of the Duodenum
    Hoeppner, Jens
    Marjanovic, Goran
    Kulemann, Birte
    Makowiec, Frank
    Hopt, Ulrich T.
    GASTROENTEROLOGY, 2012, 142 (05) : S1101 - S1101
  • [23] PET-CT evaluation of gastrointestinal stromal tumors (GIST) treated with imatinib mesylate.
    Biscontini, Giuseppina
    Nonni, Marco
    Cinti, Paolo
    Rossi, Brunella
    Ascoli, Giorgio
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [24] Comparison of PET, CT, and dual-modality PET/CT for monitoring of Imatinib (ST1571) therapy in patients with gastrointestinal stromal tumors (GIST).
    Antoch, G
    Kanja, J
    Freudenberg, LS
    Bauer, S
    Schuette, J
    Bockisch, A
    Debatin, JF
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 24P - 24P
  • [25] Clinical significance of 18F-FDG PET/CT imaging in 32 cases of gastrointestinal stromal tumors
    Du, Wen
    Cui, Guojin
    Wang, Kaiping
    Li, Shaojie
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2022, 27 (01)
  • [26] Clinical significance of 18F-FDG PET/CT imaging in 32 cases of gastrointestinal stromal tumors
    Wen Du
    Guojin Cui
    Kaiping Wang
    Shaojie Li
    European Journal of Medical Research, 27
  • [27] Getting the GIST: a pictorial review of the various patterns of presentation of gastrointestinal stromal tumors on imaging
    Scola, Dominic
    Bahoura, Lawrence
    Copelan, Alexander
    Shirkhoda, Ali
    Sokhandon, Farnoosh
    ABDOMINAL RADIOLOGY, 2017, 42 (05) : 1350 - 1364
  • [28] Imaging, morphologic, and immunohistochemical correlation in gastrointestinal stromal tumors (GIST)
    不详
    CANCER CYTOPATHOLOGY, 2005, 105 (05): : 340 - 341
  • [29] Getting the GIST: a pictorial review of the various patterns of presentation of gastrointestinal stromal tumors on imaging
    Dominic Scola
    Lawrence Bahoura
    Alexander Copelan
    Ali Shirkhoda
    Farnoosh Sokhandon
    Abdominal Radiology, 2017, 42 : 1350 - 1364
  • [30] FDG-PET as a predicitve marker for primary resistance to imatinib (IM) in patients with gastrointestinal stromal tumors (GIST).
    Oosting, S.
    Den Hollander, M. W.
    Rikhof, B.
    Rouw, D. B.
    De Jong, J. R.
    Jager, P. L.
    Brouwers, A. H.
    Van der Graaf, W. T.
    De Vries, E.
    Gietema, J. A.
    Reyners, A. K. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)